Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Stock analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Oncolytics Biotech in a research report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.39) per share for the year, up from their prior estimate of ($0.40). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2027 earnings at ($0.12) EPS.
Oncolytics Biotech Price Performance
Shares of ONC remained flat at C$0.91 during mid-day trading on Thursday. The stock had a trading volume of 28,900 shares, compared to its average volume of 123,307. The company has a 50-day moving average price of C$1.09 and a two-hundred day moving average price of C$1.30. The company has a market cap of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35. Oncolytics Biotech has a one year low of C$0.86 and a one year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recommended Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
